Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 375
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2250647-e2250647
Open Access | Times Cited: 125
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88
Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients
Benoît Misset, Michaël Piagnerelli, Eric A. J. Hoste, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 17, pp. 1590-1600
Open Access | Times Cited: 48
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
Daniele Focosi, Scott A. McConnell, Arturo Casadevall
Drug Resistance Updates (2022) Vol. 65, pp. 100882-100882
Open Access | Times Cited: 40
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 25
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 8
COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens
Sterlin T. Raj, Alexander W. Bruce, Muralidharan Anbalagan, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 8
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 41
Open Access | Times Cited: 5
Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning
Katharina Röltgen, Scott D. Boyd
Annual Review of Pathology Mechanisms of Disease (2023) Vol. 19, Iss. 1, pp. 69-97
Open Access | Times Cited: 14
Safety of COVID‐19 convalescent plasma: A definitive systematic review and meta‐analysis of randomized controlled trials
Massimo Franchini, Mario Cruciani, Arturo Casadevall, et al.
Transfusion (2023) Vol. 64, Iss. 2, pp. 388-399
Closed Access | Times Cited: 12
The Potential Role of Passive Antibody-Based Therapies as Treatments for Monkeypox
Evan M. Bloch, David J. Sullivan, Shmuel Shoham, et al.
mBio (2022) Vol. 13, Iss. 6
Open Access | Times Cited: 19
Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210)
Cristina Ferreras, Clara Hernández-Blanco, Alejandro Martín‐Quirós, et al.
Cytotherapy (2023) Vol. 26, Iss. 1, pp. 25-35
Closed Access | Times Cited: 11
An update on SARS-CoV-2 immunization and future directions
Rashmi Rana, Ravi Kant, Tanya Kumra, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
‪Yasmin Maor‬‏, Eilat Shinar, Marina Izak, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 7, pp. 964-971
Open Access | Times Cited: 10
Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: analyses by neutralising antibodies homologous to recipients’ variants
Tuba Khawaja, Mikael Kajova, Iris Levonen, et al.
Infectious Diseases (2024) Vol. 56, Iss. 6, pp. 423-433
Open Access | Times Cited: 3
Passive immunotherapies for the next influenza pandemic
Daniele Focosi, Massimo Franchini, Jonathon W. Senefeld, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 3
Closed Access | Times Cited: 3
Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation
Hyung Park, Chang Yu, Liise‐anne Pirofski, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
Massimo Franchini, Arturo Casadevall, Michael J. Joyner, et al.
Life (2023) Vol. 13, Iss. 1, pp. 134-134
Open Access | Times Cited: 9
Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
Hung Van Nguyen, Hoang Linh Nguyen, Pham Dang Lan, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 18, pp. 6497-6553
Closed Access | Times Cited: 9
Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience
Massimo Franchini, Claudia Glingani, Giuseppe De Donno, et al.
Life (2022) Vol. 12, Iss. 3, pp. 420-420
Open Access | Times Cited: 15
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
Life (2024) Vol. 14, Iss. 2, pp. 214-214
Open Access | Times Cited: 2
Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2
Thierry Burnouf, Birgit Gathof, Evan M. Bloch, et al.
Transfusion Medicine Reviews (2022) Vol. 36, Iss. 3, pp. 125-132
Open Access | Times Cited: 12
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study
Luther A. Bartelt, Alena J. Markmann, Bridget Nelson, et al.
mBio (2022) Vol. 13, Iss. 5
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top